本報道最初發(fā)表于Endpoints News。請點(diǎn)擊這里查看原文
Earlier this year, the Belgian cell therapy startup EsoBiotec had only 12 employees and had raised €22 million to develop a cutting-edge infusion that turns a patient’s immune cells into destroyers of disease.
今年早些時候，比利時細(xì)胞治療初創(chuàng)公司EsoBiotec僅有12名員工，已籌集2200萬歐元，用于開發(fā)一款前沿輸注療法，可將患者的免疫細(xì)胞轉(zhuǎn)化為“疾病殲滅者”。
您已閱讀3%（320字），剩余97%（10217字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。